(Q33587032)

English

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

major depressive disorder

1 reference

based on heuristic

inferred from title

Madhukar Trivedi

3

object named as

Madhukar H Trivedi

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

4

object named as

Maurizio Fava

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Michael E Thase

2

object named as

Michael E Thase

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

J Craig Nelson

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Jian Han

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Quynh Van Tran

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Andrei Pikalov

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Ying Qi

8

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Berit X Carlson

9

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Ronald N Marcus

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Robert M Berman

11

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Primary Care Companion to the Journal of Clinical Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

344-352

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

Selective serotonin-reuptake inhibitor-induced movement disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

A rating scale for drug-induced akathisia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

21 June 2018

RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Adjunctive aripiprazole in treatment-resistant bipolar depression.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2805571

31 October 2018

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

https://pubmed.ncbi.nlm.nih.gov/20098527

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4088/PCC.08M00744GRE

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33587032&oldid=1739017820"